Aurobindo Pharma has received the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status from the US Food and Drug Administration (USFDA) for its Unit VIII, API manufacturing facility at Gaddapotharam, Hyderabad. The USFDA had inspected company's Unit VIII from October 21, 2019 and October 28, 2019.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
